New opportunities to treat patients with high cardiovascular risk


Cite item

Full Text

Abstract

At present, combined antihypertensive therapy has become one of the main directions of the treatment of arterial hypertension, especially with the use of fixed combinations (FC). Among the most effective combinations of antihypertensive drugs is a combination of angiotensin-converting enzyme inhibitors and calcium antagonists. Since almost 70% of patients show an increase in cholesterol, it is advisable to join the treatment with drugs from the group of statins. Abroad, in recent years, the creation of a polypyle - FC 3 or more components that affect different risk factors for the development of cardiovascular diseases is widely discussed. To the polypyle can be attributed FC, which includes an inhibitor of the angiotensin-converting enzyme lisinopril, calcium antagonist amlodipine and a lipid-lowering drug from the group of statins rosuvastatin. Use of this drug is expected to increase adherence to treatment and, accordingly, the effectiveness of therapy for patients with high cardiovascular risk.

About the authors

G. A Baryshnikova

Central State Medical Academy of the President of the Russian Federation

Email: bargalan@mail.ru
д-р мед. наук, проф. каф. семейной медицины с курсами клинической лабораторной диагностики, психиатрии и психотерапии 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 21

S. A Chorbinskaya

Central State Medical Academy of the President of the Russian Federation

д-р мед. наук, проф., зав. каф. семейной медицины с курсами клинической лабораторной диагностики, психиатрии и психотерапии 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 21

References

  1. Чазова И.Е., Жернакова Ю.В., Ощепкова Е.В. и др. Распространенность факторов риска развития сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014; 54 (10): 4-12.
  2. Чукаева И.И. Что такое приверженность к лечению и что можно сделать для ее улучшения (на примере артериальной гипертонии). Лечебное дело. 2012; 2: 21-6.
  3. Wald N.J, Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-23.
  4. Bonaa K.H et al. the NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEJM 2006; 354: 1578-88.
  5. Danchin N, Cambou J.P, Hanania G et al. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 2005; 150: 1147-53.
  6. Castellano J.M, Sanz G, Penalvo J.L et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64 (20): 2071-82.
  7. Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009; 373: 1341-51.
  8. The Indian Polycap Study (TIPS). 2009.
  9. Dudl R.J, Wang M.C, Wong M Bellows. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am J Manag Care 2009; 15: e88-e94.
  10. Gaziano T.A, Opie L.H, Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet 2006; 368: 679-86.
  11. Kumar A, Fonarow G.C, Eagle K.A et al. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. Crit Pathw Cardiol 2009; 8: 104-11.
  12. Sever P.S, Dahlof B, Poultier N.R et al. Potential synergy between lipid-lowering and blood- pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982-8.
  13. Morgado M, Rolo S, Macedo A.F, Castelo-Branco M. Association of statin therapy with blood pressure control in hypertensive hypercholesterolemic outpatients in clinical practice. J Cardiovasc Dis Res 2011; 2 (1): 44-9.
  14. Watanabe K, Izumi T, Miyakita Y et al. Efficacy of amlodipine besilate therapy for variant angina: evaluation by 24-hour Holter monitoring. Cardiovasc Drugs Ther 1993; 7: 923-8.
  15. Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipin on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.
  16. Dahlof B, Sever P.S, Poulter N.R et al. Prevention of cardiovascular events with an Antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofluazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895-906.
  17. Jamerson K.A, Weber M.A, Bakris G.L et al. on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.
  18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97.
  19. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и всероссийского научного общества кардиологов). м., 2013.
  20. Рекомендации по диагностике и лечению артериальной гипертонии ESH и ESC. Евразийский кардиол. журн. 2014; 1: 7-76.
  21. Nissen S.E, Tuzcu E.M, Schoenhagen P et al: REVERSAL Investigators. Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291: 1071-80.
  22. Nissen S.E, Nicholls S.J, Sipahi I et al: ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65.
  23. Jones P.H, Davidson M.H, Stein E.A et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses. Am J Cardiol 2003; 92: 152-60.
  24. Emerging Risk Factors Collaboration: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
  25. Effectiveness and safety of combined antihypertensive and cholesterol-reducing therapy (lisinopril-amlodipine and rosuvastatin) in high and very high risk patient populations. Cardiologia Hungarica 2015; 45: 71.
  26. Галеева 3.M., Галявич А.С. Фиксированная комбинация лизиноприла с амлодипином в сочетании с розувастатином у больных гипертонической болезнью и ишемической болезнью сердца. Терапевт. арх. 2014; 9: 71-6.
  27. Драпкина O.M., Корнеева O.H., Зятенкова Е.В. и др. Розувастатин у пациентов с артериальной гипертензией и дислипидемией: влияние на микроциркуляцию и свойства пульсовой волны. Лечащий врач. 2013; 3: 1-4.
  28. Карпов Ю.А., Лялина C.B. Исследование ТРИУМВИРАТ: снижение риска развития сердечно-сосудистых осложнений у больных артериальной гипертонией с помощью трехкомпонентной комбинации антигипертензивных и липидснижающих препаратов. Кардиология. 2015; 55 (9): 10-5.
  29. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. М., 2012.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies